Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
11.54
-1.02 (-8.12%)
Feb 21, 2025, 4:00 PM EST - Market closed
Gyre Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2023 | FY 2022 |
| Feb '25 Feb 21, 2025 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Market Capitalization | 990 | 1,967 | - |
| Enterprise Value | 967 | 1,946 | - |
| Last Close Price | 11.54 | 25.69 | - |
| PS Ratio | 8.98 | 17.34 | - |
| PB Ratio | 15.67 | 25.07 | - |
| P/FCF Ratio | - | 113.23 | - |
| P/OCF Ratio | 399.83 | 75.99 | - |
| EV/Sales Ratio | 9.21 | 17.15 | - |
| EV/EBITDA Ratio | 81.94 | 95.72 | - |
| EV/EBIT Ratio | 93.20 | 101.27 | - |
| EV/FCF Ratio | - | 111.99 | - |
| Debt / Equity Ratio | 0.02 | 0.01 | 0.01 |
| Debt / EBITDA Ratio | 0.14 | 0.02 | 0.06 |
| Debt / FCF Ratio | - | 0.02 | 0.11 |
| Asset Turnover | - | 1.13 | - |
| Inventory Turnover | - | 0.89 | - |
| Quick Ratio | 3.11 | 2.49 | 3.33 |
| Current Ratio | 3.72 | 2.85 | 4.06 |
| Return on Equity (ROE) | -85.32% | -113.45% | - |
| Return on Assets (ROA) | - | 11.93% | - |
| Return on Capital (ROIC) | 6.54% | 15.83% | - |
| Return on Capital Employed (ROCE) | 9.39% | 19.91% | 12.69% |
| Earnings Yield | -8.97% | -4.72% | - |
| FCF Yield | -0.22% | 0.88% | - |
| Buyback Yield / Dilution | -28.56% | 13.02% | - |
| Total Shareholder Return | -28.56% | 13.02% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.